Early Data Suggest Novo Nordisk's Degludec Comparable To Sanofi's Lantus

Novo Nordisk has a good start for its ultra-long acting insulin Degludec, with much-anticipated Phase II data released at the American Diabetes Association annual scientific sessions June 25 showing that Degludec is as good as Sanofi-Aventis's Lantus (insulin glargine). However, to unseat the market leader, the Danish firm will need to show its insulin analog is superior in either maintaining blood glucose control or reducing the incidence of hypoglycemia